ArticleOncology letters2011
Revisiting cutaneous adverse reactions to pemetrexed.
Article in Oncology letters, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 33 citations in OpenAlex.
- Younger age as a risk factor for rash development in pemetrexed and carboplatin treatment with dexamethasone prophylaxis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- A low-dose pemetrexed-cisplatin combination regimen induces significant nephrotoxicity in mice.BMC nephrology · 2024Article
- Edema of the face and extremities secondary to pemetrexed.JAAD case reports · 2023Article
- Case Report: Chemotherapy-Associated Systemic Sclerosis: Is DNA Damage to Blame?Frontiers in medicine · 2022Article
- Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity.Drug safety · 2021Review
- Atypical Skin Manifestations During Immune Checkpoint Blockage in Coronavirus Disease 2019-Infected Patients With Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2020Article
- Slowly developing toxic epidermal necrolysis-like reaction associated with pemetrexed and carboplatin.Ecancermedicalscience · 2020Article
- Pemetrexed Induced Life-threatening Anaphylaxis.Cureus · 2019Article
- Novel anticancers and dermatological adversities: old rivals but new challenges.BMJ case reports · 2018Article
- Pemetrexed-induced radiation recall dermatitis in a patient with lung adenocarcinoma: case report and literature review.Journal of thoracic disease · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pemetrexed (Alimta®) is a multitargeted antifolate drug approved as a single agent or in combination with cisplatin for the treatment of a small number of malignancies including advanced and metastatic non-squamous non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma. This review reports the recent peer-reviewed publications and original findings regarding cutaneous adverse reactions (CARs) to pemetrexed. Pemetrexed-related CARs are frequently reported under the unspecific term 'skin rash'. However, more specific diseases were tentatively identified as alopecias, urticarial vasculitis, acute generalized exanthematous pustulosis, toxic epidermal necrolysis, radiation recall dermatitis and pityriasis lichenoides. Most of the skin reactions occur shortly after pemetrexed administration. As with methotrexate-related CARs, the cell cycle arrest in the S phase may be regarded as a direct and major cause of the cytotoxic pathobiology. An adverse immune reaction is unlikely. In conclusion, pemetrexed is responsible for CARs exhibiting a variety of clinical presentations. Their origin is likely attributed to direct cytotoxicity following the cell cycle arrest in the S phase and cell necrosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.